Valo Therapeutics acquires PeptiCHIP technology

Valo Therapeutics, a developer of immunotherapy platforms for cancer and infectious diseases, has acquired an innovative tumor ‘fingerprint’ identification technology, called PeptiCHIP.

The privately-held Finnish company has announced the exclusive licensing of intellectual property rights from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. It will enable Valo to rapidly identify tumor antigens for the development of new cancer immunotherapies using its existing technologies and opens up the possibility for a tumor-specific personalized approach in the future.

PeptiCHIP technology consists of a microfluidic chip for identification of neoantigens, coupled with a software algorithm that identifies immunogenic peptides. Together, the device and software form an easy-to-use lab tool that enables the fast and accurate identification of tumor antigen profiles. As PeptiCHIP offers advantages in comparison to existing antigen identification approaches, Valo expects to be able to commercialize the technology.